Detail akcie Pulse Biosciences online

Business Summary: Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Pulse Biosciences Inc revenues was not reported. Net loss increased 9% to $21.5M. Higher net loss reflects Stock-based Compensation in R&D increase from $776K to $2M (expense), Stock-based Compensation in SGA increase of 47% to $1.9M (expense), General and administrative - Balancing increase of 8% to $6.5M (expense).